Andrea Leigh Zaenglein, MD Professor of Dermatology and Pediatrics, Department of Dermatology, Hershey Medical Center, Pennsylvania State University College of Medicine
Andrea Leigh Zaenglein, MD is a member of the following medical societies: American Academy of Dermatology , Society for Pediatric Dermatology
Disclosure: Received consulting fee from Galderma for consulting; Received consulting fee from Valeant for consulting; Received consulting fee from Promius for consulting; Received consulting fee from Anacor for consulting; Received grant/research funds from Stiefel for investigator; Received grant/research funds from Astellas for investigator; Received grant/research funds from Ranbaxy for other; Received consulting fee from Ranbaxy for consulting.
Meloxicam use can result in gastrointestinal toxicity and bleeding, headaches, rash, and very dark or black stool (a sign of intestinal bleeding). Like other NSAIDs , its use is associated with an increased risk of cardiovascular events such as heart attack and stroke .  It has fewer gastrointestinal side effects than diclofenac ,  piroxicam ,  naproxen ,  and perhaps all other NSAIDs which are not COX-2 selective.  Although meloxicam inhibits formation of thromboxane A, it does not appear to do so at levels that would interfere with platelet function.
Limited data suggest a possible role of ketorolac in the management of other forms of acute pain, such as renal colic, biliary colic, sickle cell crisis or migraine headaches. Ketorolac is also useful in patients with a history of opiate dependency. It can be combined with opiate analgesia to achieve a sparing effect, although it will not prevent opiate withdrawal symptoms. If a patient receiving a low dose of ketorolac (., 15 mg every six hours) experiences a return of pain before the next dose, the dose may be increased to 30 mg before a narcotic analgesic is added or substituted.